Vol. 2 No. 11 (2022)
Reimbursement Recommendations

Empagliflozin (Jardiance)

Published November 1, 2022

Key Messages

  • CADTH recommends that Jardiance should be reimbursed for the treatment of chronic heart failure as an adjunct to standard-of-care therapy if certain conditions are met.
  • Jardiance should only be covered to treat patients 18 years and older whose heart is unable to pump enough blood to keep up with the body’s needs (heart failure) because the heart is either too weak (heart failure with reduced ejection fraction [HFrEF]) or too stiff (heart failure with preserved ejection fraction [HFpEF]). The patient should either have a slight limitation in physical activity (New York Heart Association [NYHA] functional classification class II) or a marked limitation in physical activity (NYHA class III).
  • Jardiance should only be reimbursed if the price is less costly than dapagliflozin for the treatment of chronic heart failure. Jardiance should be prescribed as an added therapy to standard therapy for chronic heart failure.